Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
about
A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-AnalysisBleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interruptedMy Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation.Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation.Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.Evaluation of left atrial thrombus prior to catheter ablation of atrial fibrillation: Is it time for an individualized approach?Complications of Atrial Fibrillation Cryoablation.European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial designAntithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Soc
P2860
Q34109813-ACDB4969-8958-4E68-9D7F-75541CBC0B98Q35631782-1B30F21E-A9BF-4A6B-9CD7-3B6E9A9B6428Q35765335-F6091A39-B96E-4D34-B647-0D8DF43E933EQ35868819-D795D93D-14C7-4C95-8CB5-285658A50030Q36240734-E360F6F7-4120-4D9D-BFA3-D24A8F5E12F8Q36247011-441E223F-22DB-4529-94E3-E57A1654F52AQ37115545-478A3EBD-F4EC-4553-8E31-D7AE2B1799DBQ37623666-D5E62747-EAC4-41B9-959D-D9D6EAFB21CAQ38365022-BEEB1C45-26D9-43D1-955B-C30CE6A3D0FAQ38386998-B9CE0D86-9A69-4996-AD88-11CCC890B463Q38398014-FBFEBC8F-2198-495B-8224-299460886AA9Q38826010-6649B1CB-8321-4254-9A16-9444D8CDFCB7Q39285809-2E94EA2B-8C2B-49D2-931F-BC3C7041FCA9Q40435479-EF18B39F-3768-4F99-BBE1-CA770A5DBF91Q40891224-2D364434-82C5-4986-99FB-18B9D15CDADEQ42172443-A1AC9740-1237-4E9D-943A-E932F4D735DBQ42373398-3F429581-ECAB-431E-9871-4638132936C6Q45059153-E150A5D2-5FF7-4CF3-97DE-580B03C1D6EBQ45069696-80AA1725-78CC-4F80-8488-F8A6C666E592Q46658026-993ACD36-AEE7-409F-BDC1-F1FDB6ED0236Q47118947-62090804-4227-41ED-8F32-6C0C2D273A3DQ48344720-036D8A70-EDDA-4DE9-BB8F-758EC42508DDQ50297967-FAF5B8C0-EA53-4666-9C51-45C762667798Q55208569-97C5C0E3-2AC9-4F60-902C-5BAC68369103Q55263071-65329702-9EA9-41C2-AF50-B73A1A1F1CE0Q57626457-3157FA52-EB38-48C6-B18C-A452382E3468
P2860
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Rivaroxaban and dabigatran in ...... lation of atrial fibrillation.
@en
type
label
Rivaroxaban and dabigatran in ...... lation of atrial fibrillation.
@en
prefLabel
Rivaroxaban and dabigatran in ...... lation of atrial fibrillation.
@en
P2093
P50
P921
P356
P1433
P1476
Rivaroxaban and dabigatran in ...... blation of atrial fibrillation
@en
P2093
Eloi Marijon
François Jourda
Hassiba Hireche
Jean-Paul Albenque
Nicolas Combes
Stéphane Combes
P304
P356
10.1093/EUROPACE/EUU007
P577
2014-02-18T00:00:00Z